Citi has issued an update on Pharmasset Inc VRUS and ther final cure rate from the ph2 study.
According to the report, "Pharmasset just announced the final cure rate (SVR24) from the ph 2 study in 25 pts who have genotype 2/3 type of hepC virus. Recall this represents 25-35% of all hepC pts globally and there is very little new competition to Pharmasset's PSI-7977 (nuc)."
VRUS has a Buy Rating and has a $200 Price Target.
VRUS closed at $129.39 a share yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in